Г. Д. Даниярова

https://orcid.org/0000-0001-5876-7528

Найдено статей: 5

  • Social efficiency of introduction of atherosclerosis screening program in Kazakhstan. Systematic review (Выпуск № 1, 2025)

    M. Bekbossynova, S. Duisekova, A. Zeinoldina, G. Daniyarova, K. Akzholova
    2025-03-31
    72–87
    Аннотация

    Background. Atherosclerosis, a major cause of cardiovascular disease, has a significant impact on morbidity and mortality in Kazakhstan. The increasing burden of this disease, combined with a high prevalence of dyslipidemia, underscores the importance of effective screening to reduce associated health risks. The aim of this study is to evaluate the social efficiency of implementing a nationwide atherosclerosis screening program in Kazakhstan and to assess its potential to improve public health outcomes and reduce mortality from cardiovascular disease.

    Methods. A literature review was conducted, and global screening approaches and protocols for atherosclerosis and cardiovascular disease were analyzed for their applicability in the local context.

    Results. Results suggest that targeted and cascade screening programs, particularly those focused on high-risk individuals and familial hypercholesterolemia, are effective in reducing disease incidence and mortality. Implementation of similar protocols in Kazakhstan could improve early detection, allowing for preventive interventions and treatment. The study concludes that a structured, government-sponsored screening program would not only save lives but also provide substantial economic benefits by reducing long-term health care costs associated with cardiovascular complications.

    Conclusion. Screening is the convenient and economically efficient way to prevent atherosclerosis, and its effectiveness is demonstrated by worldwide practice and the history of early disease prevention. However, the effectiveness and social value of screening need to be demonstrated before it can be incorporated into medical practice. If established as a regular practice, widespread population screening could dramatically reduce cardiovascular disease, the leading cause of death worldwide.

    Ключевые слова

    atherosclerosis, dyslipidemia, cardiovascular diseases, lipid profile, screening

  • Correlation between apolipoprotein b/a1 and the risk of metabolic-related fatty liver disease depending on the lipid profile (Выпуск № 1, 2025)

    M. Bekbossynova, G. Myrzakhmetova, S. Seitkasym, A. Sailybaeva, S. Khamitov, G. Daniyarova, K. Akzholova
    2025-03-31
    29–36
    Аннотация

    Background. The aim of this study was to investigate the relationship between the Apolipoprotein B/Apolipoprotein A1 ratio and the risk of metabolically associated fatty liver disease, considering lipid profile variations and determine whether the Apolipoprotein B/Apolipoprotein A1 ratio can serve as an independent predictor of metabolically associated fatty liver disease and its associated cardiovascular risks.

    Methods. A total of 377 patients diagnosed with cardiovascular disease and coexisting metabolically associated fatty liver disease were stratified into high-risk and very high-risk groups based on established clinical and imaging criteria. Lipid profiles, Apolipoprotein B, and Apolipoprotein A1 levels were measured, and their associations with cardiovascular and metabolic parameters were analyzed using correlation and regression models.

    Results. The findings reveal a strong positive correlation between Apolipoprotein B levels and atherogenic lipid markers such as low-density lipoproteins cholesterol and total cholesterol, as well as a moderate correlation with triglycerides. In contrast, Apolipoprotein A1 demonstrated a strong positive association with high-density lipoproteins cholesterol and an inverse correlation with metabolic indicators such as Hemoglobin A1c and glucose, suggesting a potential protective role. The Apolipoprotein B/Apolipoprotein A1 ratio emerged as a more accurate predictor of cardiovascular and metabolic risk than traditional lipid ratios. Furthermore, the Apolipoprotein B/Apolipoprotein A1 ratio was significantly associated with the presence and severity of metabolically associated fatty liver disease, reinforcing its potential utility as a biomarker for metabolic liver disease.

    Conclusion. This study highlights the clinical relevance of incorporating apolipoprotein measurements into the routine assessment of individuals at risk for metabolic and cardiovascular disease.

    Ключевые слова

    Apolipoprotein B, Apolipoprotein A1, metabolic-associated fatty liver disease, cardiovascular disease, lipid metabolism, dyslipidemia, risk assessment

  • Single-center experience of heart transplantation at the heart center of Astana (Выпуск № 3, 2024)

    Y. Pya, A.A. Abdiorazova, S.Kh. Altynova, G.Sh. Myrzakhmetova, S.P. Novikova, A.Y. Goncharov, Y.S. Yakhimovich, G.D. Daniyarova
    2024-09-30
    46–53
    Аннотация

    Background. Chronic heart failure is a major global health issue. As a complication of most cardiovascular diseases, it affects 4% of the population. Heart transplantation is the gold standard in the treatment of patients with end-stage heart failure. Objective of the study was to evaluate early and long-term outcomes of heart transplants performed at the Heart Center University Medical Center (Heart Center) over a 10-year period.

    Materials and methods. Cross-sectional study was conducted from 2012 to 2022, 86 orthotopic heart transplants were performed at the Heart Center. The analysis of the obtained results was conducted retrospectively.

    Results. From August 2012 to December 2022, 114 patients were on the waiting list for heart transplantation. Of these, 86 (75.4%) patients underwent transplantation; 10 (8.7%) patients were excluded. Among the 86 patients, 49 (56.9%) had previously undergone cardiac surgery. Of these, 42 (48.8%) had a left ventricular assist device implanted earlier, 3 (3.4%) had a fully artificial heart, and 2 (2.5%) were on temporary mechanical support (central veno-arterial Extracorporeal membrane oxygenation). Hospital mortality was 8 (9.3%) recipients. In 2.7% of cases, the cause of death was an acute cerebrovascular accident on the second day post-surgery. Postoperative renal dysfunction was noted in 28 (32.5%) patients. An analysis of all performed heart transplantation cases showed a 30-day survival rate of 94%, a 1-year survival rate of 84.3%, and a 5-year survival rate of 64.7%.

    Conclusion. In the hospital period and the first 6 months after heart transplantation, infectious-septic complications were predominant, whereas in later periods, rejection reactions were more common.

    Ключевые слова

    Heart transplantation, heart failure, mechanical circulatory support, immunosuppression

  • Особенности течения неалкогольной жировой болезни печени при сахарном диабете 2 типа и нарушении толерантности к глюкозе (Выпуск № 2, 2024)

    М. С. Бекбосынова, Г. Ш. Мырзахметова, Ш. К. Сейткасым, А.И. Сайлыбаева, С.Р. Хамитов, Ж. О. Оралбекова, Г. Д. Даниярова
    2024-06-28
    39–49
    Аннотация

    Фон. Неалкогольная жировая болезнь печени и сахарный диабет 2 типа или нарушение толерантности к глюкозе являются распространёнными заболеваниями с высоким риском развития сердечно-сосудистых заболеваний, основной причиной инвалидности и смерти. Наша цель - разработать новые методы скрининга, профилактики и лечения сердечно-сосудистых заболеваний у пациентов с вышеуказанными заболеваниями. Методы и методология. Данное исследование является одно-центровым, открытым, неконтролируемым, диагностическим. В период с 2023 по февраль 2024 года в Кардиологическом центре «Университетский медицинский центр» Корпоративного фонда отобрано 216 пациентов с сердечно-сосудистыми заболеваниями и сопутствующей неалкогольной жировой болезнью печени, сахарным диабетом 2 типа и нарушением толерантности к глюкозе.

    Результаты. У всех обследованных больных с сердечно-сосудистыми заболеваниями и сопутствующей неалкогольной жировой болезнью печени выявлено повышение активности печеночных ферментов. Показатели липидного профиля крови достоверно превышали оптимальные уровни для пациентов с сердечно-сосудистыми заболеваниями. Также отмечено достоверное увеличение ферментов печени, С-реактивного белка, триглицеридов и малого липопротеина у пациентов с сердечно-сосудистыми заболеваниями и неалкогольной жировой болезнью печени в сочетании с сахарным диабетом 2 типа и нарушением толерантности к глюкозе. Выводы. Анализ активности ферментов печени, С-реактивного белка, глюкозы и липидограммы показал достоверное увеличение этих показателей у пациентов с сердечно-сосудистыми заболеваниями и неалкогольной жировой болезнью печени, особенно при наличии сахарного диабета 2 типа и нарушения толерантности к глюкозе. У всех обследованных больных наблюдалось повышение активности ферментов печени и уровня липидов, что свидетельствует о влиянии этих заболеваний на печень и обмен веществ.

    Ключевые слова

    Неалкогольная жировая болезнь печени, Сахарный диабет 2 тип, толерантность к глюкозе, Сердечно-сосудистые заболевания, Метаболический синдром

  • Связь между уровнем общего билирубина и частотой развития атеросклероза: систематический обзор и мета-анализ (Выпуск № 2, 2024)

    М. С. Бекбосынова, Т. В. Иванова-Разумова, А. Ержан, Г. Д. Даниярова, С. Р. Хамитов
    2024-06-28
    32–38
    Аннотация

    Өзектілігі. Билирубин-эритроциттердің ыдырауының жанама өнімі. Билирубин деңгейі жүрек-қан тамырлары қаупін бағалау үшін биомаркер бола алады. Бұл зерттеуде біз сарысулық билирубин деңгейінің атеросклероздың прогрессиясымен байланысын зерттеген соңғы 5 жылда жарияланған ең соңғы қолжазбаларды зерттеп, жалпы билирубин деңгейінің аурудың дамуын қаншалықты төмен болжай алатынын анықтаймыз.

    Әдістері. PubMed іздеу жүйесінің көмегімен "билирубин" және "атеросклероз"кілттік сөздері бар барлық мақалалар табылды. 2019-2023 жылдар кезеңінде, соңғы 5 жылда барлығы 67 іздеу нәтижелері пайда болды. Мета-талдау үшін жалпы билирубин концентрациясы мен атеросклероздың дамуы арасындағы байланысты зерттейтін 6 популяциялық зерттеу қолданылды.

    Нәтижелер. қандағы жалпы билирубин деңгейінің жоғарылауы атеросклероздың даму ықтималдығын төмендетеді, яғни жалпы билирубин деңгейі мен артериялық бляшкалардың пайда болуы немесе стеноз арасында кері байланыс бар. Біріктірілген коэффициент 0.86 (95% СИ 0.83–0.9) болды, бұл ммоль/л үшін билирубин деңгейінің әрбір жоғарылауымен атеросклероздың даму ықтималдығы 14% төмендейтінін көрсетеді. Жалпы, сарысудағы жалпы билирубиннің жоғары деңгейі атеросклероздың даму қаупінің айтарлықтай төмендеуімен байланысты болды.

    Қорытынды. Мета-талдау жалпы билирубиннің төмен деңгейі мен атеросклероздың даму қаупі арасындағы айтарлықтай кері байланысты көрсетеді, бұл билирубиннің жоғары деңгейі аурудың дамуынан қорғай алады деп болжайды.

    Ключевые слова

    Уровень Общего Билирубина, Атеросклероз, Мета-анализ, Сердечно-Сосудистая Система